Relmada Therapeutics, Inc. (RLMD)
7.01
+0.26
(+3.85%)
USD |
NASDAQ |
Apr 08, 16:00
7.01
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Enterprise Value : 642.27M for April 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals, Inc. | 2.385B |
| Theravance Biopharma, Inc. | 614.92M |
| Avalo Therapeutics, Inc. | 232.44M |
| AN2 Therapeutics, Inc. | 62.04M |
| ACADIA Pharmaceuticals, Inc. | 3.079B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.87M |
| Total Expenses (Quarterly) | 19.87M |
| EPS Diluted (Quarterly) | -0.2911 |
| Earnings Yield | -20.19% |
| Normalized Earnings Yield | -20.28 |